Roche's Gazyva could become the first drug to gain approval in membranous nephropathy, pending regulatory decisions from the ...

Eli Lilly is dropping the development of three therapies that did not meet expectations, including an acquired gene therapy.

As the oral weight loss drug market has started to emerge, AstraZeneca has told shareholders that it will advance its ...

Clinical trials are facing new and evolving challenges as costs increase and approval timelines remain lengthy. Modernisation ...

TransCode Therapeutics, in partnership with Quantum Leap Healthcare Collaborative, has submitted an IND application amendment ...

Evommune’s potential Dupixent competitor has met its primary endpoint in a Phase IIa atopic dermatitis (AD) trial, achieving a 33% reduction in Eczema Area and Severity Index (EASI).

The Medicines and Healthcare products Regulatory Agency (MHRA) is formalising its review process around in vitro diagnostics ...

This comes as Upstream Bio's twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing severe asthma exacerbations.

Nektar will now take Treg therapy, rezpeg to a Phase III trial in atopic dermatitis (AD), which is set to begin in Q2 2026.

Pfizer will be speaking with authorities about the combination following the Phase III readout. Photo by SOPA Images/LightRocket via Getty Images. Another of Pfizer’s Braftovi regimens has shown ...

The impact of Covid-19 pandemic included various downstream effects on health endpoints worldwide, including the increase in substance abuse.

With ramping complexity, technology plays a key role in managing the clinical supply chain. Image credit: Corona Borealis Studio via Shutterstock Clinical development has fundamentally changed, yet ...